American Heart Association
American Heart Association
December 14, 2019
2 min read

Top news from AHA: ISCHEMIA, dapagliflozin for HF, gout drug post-MI

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Healio and Cardiology Today reported live from the American Heart Association Scientific Sessions in Philadelphia, bringing readers the latest research and breaking news in cardiology.

We bring you the most-popular articles from the meeting, in no specific order. Find more coverage from the AHA Scientific Sessions here.


ISCHEMIA: Invasive strategy, medical therapy yield similar CV outcomes in stable ischemia

In stable patients with moderate or severe ischemia, an invasive strategy and a conservative strategy of optimal medical therapy yielded similar long-term CV outcomes, according to long-anticipated results of the ISCHEMIA and ISCHEMIA-CKD trials. Read more


Dapagliflozin confers consistent benefit in HF without diabetes: DAPA-HF

New analyses of the DAPA-HF trial suggest that the benefits of the SGLT2 inhibitor dapagliflozin extend beyond its effects as a type 2 diabetes therapy. Read more


COLCOT: Low-dose colchicine reduces CV risk after MI

In the COLCOT trial, adults with a recent MI were less likely to experience an ischemic CV event over 2 years when assigned the anti-inflammatory gout medication colchicine compared with assignment to placebo. Read more


ED visits spike, prescribing patterns change in wake of valsartan recall

When multiple generic valsartan products were recalled worldwide in July 2018 due to the presence of a carcinogenic contaminant, valsartan dispensing immediately decreased. However, there was an immediate spike in ED visits for hypertension and incomplete replacement with alternative products in some patients. Read more


Evening eating may worsen heart health in women

Women who consumed a higher proportion of their daily calories after 6 p.m. had poorer overall CV health and higher BP, BMI and HbA1c levels. Read more


Icosapent ethyl shows benefit on several plaque characteristics at 9 months: EVAPORATE

Interim data using coronary CT angiography demonstrated benefits of icosapent ethyl as an adjunct to statin therapy on several plaque characteristics at 9 months in adults with high triglycerides and coronary atherosclerosis. Read more


Twice-yearly inclisiran cuts LDL in ASCVD patients

New data on inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, demonstrate sustained LDL reductions with twice-yearly dosing in high-risk patients with atherosclerotic CVD. Read more



Vitamin D, fish oil fail to reduce first HF hospitalization risk

Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions. Read more


GALILEO: Rivaroxaban raises death, thrombotic, bleeding risk vs. antiplatelet therapy after TAVR

Among patients who underwent successful transcatheter aortic valve replacement and were not on chronic oral anticoagulation, rivaroxaban was linked to higher risk for death/thromboembolic complications and bleeding compared with antiplatelet therapy. Read more


PARAGON-HF: Sacubitril/valsartan benefit in HFpEF most prominent in women, lower EF

Sacubitril/valsartan reduced the risk for HF hospitalization more in women compared with men, and the overall benefit of sacubitril/valsartan was driven by a benefit in patients with chronic HF and a left ventricular ejection fraction below the normal range, according to two analyses of the PARAGON-HF trial of patients with HF with preserved EF. Read more


Genetic testing may identify patients at risk for sudden cardiac death

Gene sequencing was used to identify a subset of the population predisposed to sudden cardiac death by a DNA variant. Read more


E-cigarette use negatively affects lipids, myocardial blood flow

Electronic cigarette use appears to have detrimental effects on lipid levels and myocardial blood flow compared with nonuse, according to results of two studies. Read more